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Introduction: Cholinergic systems are involved in learning and memory. 
Scopolamine, a muscarinic acetylcholine receptor antagonist, is used as a standard/
reference drug for inducing cognitive deficits in healthy humans and animals. The 
purpose of this study was to evaluate the effects of scopolamine on avoidance 
memory and number of neurons in rat’s hippocampus. .
Methods: Thirty five male albino Wistar rats (200 ± 20 g) were used in this study. 
The rats were divided randomly into five groups: control group (healthy samples), 
sham (saline) and 3 experimental groups 0.2, 0.5 and 1 mg/kg (intraperitoneally 
- single dose of Scopolamine). Animals were tested by passive avoidance method 
(shuttle box). After one week, a memory test was  taken from rats. Finally, with 
dissection of the rats' brains and tissue operations, neurons were stained with 
cresyl violet. Photographs of the samples in hippocampal areas were prepared, 
and neurons were counted.
Results: Our results showed that the number of neurons in all experimental 
groups was lower than that in the control group. The highest decrease in number 
of neurons was shown in response to 1 mg/kg scopolamine compared to the 
control group in all regions of hippocampus. Also, we found that in comparison 
to the saline-treated animals, the injection of scopolamine to rats after training, 
caused memory destruction. 
Discussion: We concluded that memory impairment-induced by scopolamine is 
probably associated with neuronal loss and this decrease was dose dependent. 
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               1. Introduction
oday, it is accepted that memory is one of the 
most essential roles of the brain. Memory is 
vital for survival because it is the process by 
which organisms are able to record their ex-
periences and use this information to adapt 
their responses to the environment (Dunning & During, 
2003). Gradual loss of memory and impaired cognitive 
T
functions are the major features of Alzheimer’s disease 
(AD) (Siddiqui & Levey, 1999).
The neurotransmitter of the central cholinergic system 
is involved in cognitive functions (Blokland, 1995), and 
plays an important role in learning and memory for hu-
mans and animals (Morris, Anderson, Lynch, & Baudry, 
1986; Sutherland, Whishaw, & Regehr, 1982; Winkler, 
Suhr, Gage, Thal, & Fisher, 1995). 
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Loss of memory is often the most disabling aspect of 
many disorders, impairing the normal daily activities of 
the patients. Animal models of memory impairment can 
help us understand the molecular basis of memory and 
its therapeutic targets. The model of scopolamine- in-
duced amnesia in rodents is one of the well-established 
animal models of memory dysfunction (Blokland, 
2005).
Scopolamine, a non-selective muscarinic receptor an-
tagonist, confers impairment of learning acquisition and 
short-term memory (Izquierdo, 1989) and reduces ace-
tylcholine level in the hippocampus.
Similarities have been reported in the memory deficit 
between Alzheimer’s disease patients and scopolamine 
treated animals. Thus, it has been anticipated that sco-
polamine, can provide a useful pharmacological tool to 
generate a partial model of the disorder (Azami, Jahan-
shahi, & Babapour, 2010).
The passive avoidance model has been used to study 
learning and memory for a stressful stimulus. The prac-
tice is based on the innate preference of rodents for the 
dark section of the apparatus and the suppression of this 
innate preference following exposure to an inescapable 
shock; that is, passive avoidance performance is an 
adaptive response to a stressful experience that serves 
as a measure of learning and memory (Tsuji, Takeda, & 
Matsumiya, 2003).
Recent neuroscience research demonstrated that in the 
mammalian brain two regions have neurogenesis: the 
subventricular zone of the anterior lateral ventricles and 
the subgranular zone of the dentate gyrus in the hippo-
campus (Jahanshahi, Khoshnazar, Azami, & Heidari, 
2011).
Experimental lesion of cholinergic nuclei leads to the 
suppression of neurogenesis in rat’s hippocampus (Coo-
per-Kuhn, Winkler, & Kuhn, 2004; Van der Borght et 
al., 2005). Thus, it is considered that activation of the 
central cholinergic system enhances hippocampal neu-
rogenesis, and this may contribute to the improvement 
of cognitive function (Kotani, Yamauchi, Teramoto, & 
Ogura, 2006).
Therefore, the aim of this study was to evaluate the 
effects of scopolamine (as muscarinic receptor antago-
nist) on avoidance memory and determination of sco-
polamine side effects on the number of neurons in male 
Wistar rats' hippocampal formation.
2. Materials and Methods
2.1. Animals
Thirty five male Wistar rats (Pasteur institute, Amol, 
Iran), weighting 200 ± 20 g at the time of training, were 
used in passive avoidance task. They had free access to 
food and water, were housed seven in a cage, and kept at 
controlled temperature (22 ± 2°C) under a 12/12 h light-
dark cycle (light beginning at 7:00 a.m.) at least 1 week 
before the beginning of the experiments. The rats were 
randomly distributed into five groups (n = 7) as follows:
1. Control: Without receiving scopolamine and behav-
ioral test.
2. Saline-control: received saline + behavioral test.
3. Exp.  0.2 mg/kg: received scopolamine (0.2 mg/kg 
IP) + behavioral test. 
4. Exp. 0.5 mg/kg: received scopolamine (0.5 mg/kg IP) 
+ behavioral test.   
5. Exp. 1 mg/kg: received scopolamine (1 mg/kg IP) + 
behavioral test.   
All experiments were carried out during the light phase 
between 9:00 and 15:00. Experimental groups consisted 
of 7 animals and each animal was tasted once only. All 
procedures were performed in accordance with institu-
tional guidelines for animal care and use.
2.2. Drugs
Scopolamine hydrobromide (sigma, USA) was used in 
the present study. Scopolamine was dissolved in saline 
(NaCl 0.9%) at final concentrations of 0.2, 0.5 and 1 
mg/kg, and was injected intraperitoneally one day after 
the training.
Inhibitory Avoidance Apparatus
The step-through inhibitory avoidance apparatus con-
sisted of two compartments of the same size (20 × 20 
× 30 cm3). In the middle of a dividing wall, a guillotine 
door (7.9 cm2) could be lifted manually. The walls and 
floor of one compartment consisted of white opaque 
resin and the walls of the other compartment were dark. 
Stainless steel bars (3 mm in diameter and 1 cm inter-
vals) constituted the floor of the dark compartment. In-
termittent electric shocks (50 Hz, 3 s, 1.5 mA intensity) 
were delivered to the grid floor of the dark compartment 
by an isolated stimulator.
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Behavioral Procedures
Our previous study (Azami, et al., 2010) described 
passive avoidance as follows: All animals were allowed 
to habituate in the experimental room (with light and 
sound attenuated) for at least 30 min prior to the ex-
periments. Then, each animal was gently placed in the 
brightly lit compartment of the apparatus; after 5 s the 
guillotine door was opened and the animal was allowed 
to enter the dark module. 
The latency with which the animal entered the dark 
chamber was recorded. Animals that waited more than 
120 s to enter the dark chamber were excluded from the 
experiments.
Once the animal entered with all four-paws to the next 
chamber, the guillotine door was closed and the rat was 
immediately withdrawn from the compartment. This tri-
al was repeated after 30 min. As in the acquisition trial, 
after 5s the guillotine door was opened, and as soon as 
the animal entered the dark (shock) compartment the 
door was closed; and a foot shock (50 Hz, 1 mA and 
3 s) was immediately delivered to the grid floor of the 
dark room. After 20 s, the rat was removed from the 
apparatus and placed temporarily into its home cage. 
Two minutes later, the animal was retested in the same 
way as in the previous trials; if the rat did not enter the 
dark compartment during 120 s, a successful acquisition 
of inhibitory avoidance response was recorded. Other-
wise, when the rat entered the dark compartment (be-
fore 120 s) a second time, the door was closed and the 
animal received the shock again. After retesting, if the 
rat learned inhibitory avoidance response successfully, 
it was moved to the cage and 24h after the training, re-
ceived scopolamine or saline (i.p.). On the test day (one 
week after training) each animal gently placed in the 
light compartment and after 5 s the door was opened, 
and step through latency (sec) was recorded in the ab-
sence of electric foot shocks, as indicator of inhibitory 
avoidance behavior.
Histology
24 h after the testing sessions, rats were anaesthetized 
with chloroform, decapitated and their brains were re-
moved from the skull and stored in paraformaldehyde 
(4%) for two weeks, then, the brains were placed in 
tissue processor apparatus for tissue procedures. Fol-
lowing this session, samples of the brain were embed-
ded in paraffin and kept in refrigerator. Then the brains 
were sliced coronally into 8 µm sections (from Bregma 
–2.5 mm to –4.5 mm of the hippocampal formation) 
with a rotary microtome (MK 1110) and the sections 
were stained with cresyl violet in accordance with rou-
tine laboratory procedures (Bancroft & Gamble, 2008). 
A photograph of each section was produced using an 
Olympus BX 51 microscope and a DP 12 digital cam-
era under a magnification of 1000 for Dentate Gyrus 
(DG) area and 400 for the other areas. An area of 4800 
μm2 for DG and 30000 μm2 were selected in the lower 
horn of the dentate gyrus in all sections. To measure the 
area density of the granule cells, the images were trans-
ferred to the computer. Using OLYSIA Autobioreport 
software, Olympus Co, the appropriate grids were su-
perimposed on the pictures and the cells were counted 
manually. To perform an unbiased measurement, the 
individual was double-blinded and only the cells with 
significant granule cell characteristics were counted 
(Jahanshahi, Golalipour, & Afshar, 2009; Jahanshahi, 
et al., 2011; Jahanshahi, Sadeghi, Hosseini, Naghdi, & 
Marjani, 2008).
Statistical Analysis
All data were entered into and analyzed by SPSS soft-
ware. The data were expressed as mean ± SEM. The sta-
tistical analysis was performed using one and two way 
analysis of variance (ANOVA). Post-hoc comparison of 
means was carried out with the Tukey test for multiple 
comparisons, when appropriate.
The level of statistical significance was set at P < 0.05. 
3. Results
In the experimental groups the rats were trained and 
were tested 7 days later. Table 1 shows the results of the 
memory test. As the table shows, latency of response 
in the sham group was 128.57 ± 97.48 s while for the 
experimental groups it was a much shorter time (0.2 
= 52.86±9.51 s, 0.5 = 50.86±57.32 s and 1mg/kg = 
26.57±34.07.48 s). Data showed a significant difference 
between sham and experimental groups (p < 0.05). We 
found no significant difference between the experimen-
tal groups with the other.
Tables 2, 3 and 4 show the results of cell counts in dif-
ferent groups. The number of neurons in all experimen-
tal groups was lower than in the control group and these 
differences were significant (P < 0.05). 
The highest decrease in the number of neurons was 
shown in response to scopolamine with dose of 1 mg/
kg compared to the control, in all regions of the hip-
pocampus.
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Table 1. Latency of entrance (in seconds) to dark chamber in different groups of rats
 Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7
Sham 300 40 91 79 62 231 97
0.2 mg/kg 59 54 58 57 39 63 40
0.5 mg/kg 73 29 32 4 35 12 171
1 mg/kg 40 4 10 23 6 5 98
Table 2. Number of neurons in CA1 area of Hippocampus (Mean and SD)
Groups – CA1 mean Std. Deviation P value
Control 31.87 7.158
Saline-control 33.88 6.354 0.059
Exp.  0.2 mg/kg 32.4 5.936 0.616
Exp.  0.5 mg/kg 28.58 4.749 0.002
Exp.  1 mg/kg 27.97 5.227 0.000
Table 3. Number of neurons in CA3 area of Hippocampus (Mean and SD)
Groups – CA3 Mean Std. Deviation P value
Control 23.15 5.374
Saline-control 25.63 6.244 0.003
Exp.  0.2 mg/kg 20.73 4.704 0.004
Exp.  0.5 mg/kg 20.33 3.112 0.001
Exp.  1 mg/kg 27.97 3.504 0.000
Table 4. Number of neurons in DG area of Hippocampus (Mean and SD)
Groups – DG Mean Std. Deviation P value
Control 20.98 3.789
Saline-control 19.33 3.564 0.004
Exp.  0.2 mg/kg 18.47 2.819 0.000
Exp.  0.5 mg/kg 19.5 2.168 0.001
Exp.  1 mg/kg 19.82 3.045 0.000
We found some increase in the number of neurons  in 
CA1 and CA3 areas of hippocampus in sham-saline 
group compared to the control group, however, this in-
crease was only significant in CA3. 
4. Discussion
This study was performed to assess whether scopol-
amine can decrease the number of neurons proliferat-
ing in the hippocampal formation, and if this can affect 
its function as inhibitory memory latency. We observed 
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good consistency between neurogenesis reduction and 
shortness of inhibitory memory latency. 
A review of the literature on scopolamine, clearly 
shows that this drug is capable of inducing various be-
havioral changes in several animal species (Robinson, 
Harbaran, & Riedel, 2004; Santi & Weise, 1995; Sav-
age, Faust, Lambert, & Moerschbaecher, 1996; Spinelli, 
Ballard, Feldon, Higgins, & Pryce, 2006), which shows 
scopolamine can cause very potent performance impair-
ment on tests of learning and memory (Hodges Jr, Lind-
ner, Hogan, Jones, & Markus, 2009; Sambeth, Riedel, 
Smits, & Blokland, 2007; Spinelli, et al., 2006). This 
would corroborate the view that scopolamine is an am-
nesic drug that disrupts central cholinergic neurotrans-
mission. 
Limbic system has an undeniable role in memory. For 
example, to clarify the role of cholinergic neurons in the 
amygdala on learning and memory, topical scopolamine 
injection into the bilateral amygdala of mice suggested 
that the site of action for scopolamine to cause antero-
grade amnesia is the amygdala, and that cholinergic 
neurons projecting to the amygdala play an important 
role in memory acquisition in the two passive avoidance 
tasks (Nomura, Nishiyama, Saito, & Matsuki, 1994).
Riekkinen in 1995, by examining the role of anterior 
and posterior cingulate cortical muscarinic receptors, 
suggested that muscarinic acetylcholine receptor antag-
onist may modulate passive avoidance performance via 
cholinergic receptors located in anterior cingulate cor-
tex and the ability to develop a spatial navigation strat-
egy via muscarinic receptors is located in the posterior 
cingulate (Riekkinen, Kuitunen, & Riekkinen, 1995).
Similar to our study, Gacar showed that scopolamine 
significantly shortened the second day latency com-
pared to the control group (Gacar et al., 2011). Also 
bilateral injection of scopolamine (2 and 4 μg/rat) into 
the dorsal hippocampus (intra-CA1) of rats decreased 
memory consolidation and induced amnesia (Jamali-
Raeufy, Nasehi, Ebrahimi-ghiri, & Zarrindast, 2011).
Many researchers have addressed the potential ef-
fectiveness of neurogenesis as a cause of hippocampal 
functions in learning and memory (Gage, Kempermann, 
Palmer, Peterson, & Ray, 1998; Shors et al., 2001; Van 
Praag, Kempermann, & Gage, 1999).
Similar to our observations in animal model system, 
Kotani in 2006 showed that scopolamine (0.75, 3 mg/
day for four weeks) decreases the number of BrdU-pos-
itive cells in the DG, compared to the control group, and 
scopolamine suppresses the survival of newborn cells 
in the DG via CREB signaling without affecting neural 
progenitor cell proliferation and the neuronal differen-
tiation. This is the first evidence that pharmacological 
manipulation of the cholinergic system can modulate 
adult hippocampal neurogenesis (Kotani, et al., 2006).
Figure 1. CA1 area of hippocampus in all groups. A= Control, B= Sham, C= 0.2 mg/kg, 
D= 0.5 mg/kg and E= 1 mg/kg
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As a drug model, Konar in 2011 found that scopol-
amine hydrobromide (1, 3, 6, 10 mg/kg),  administered 
intraperitoneally to mice, caused dose and time depen-
dent down regulation of the  BDNF and GFAP expres-
sion (Konar et al., 2011).
Conclusion
We concluded that scopolamine, as a non-selective 
muscarinic receptor antagonist, can significantly short-
en the latency compared to the saline-control group in 
test day. Also it can reduce the number of neurons in 
sub-regions of hippocampal formation.
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